[Predictive factors for clinically significant elevation of post-prostatectomy Gleason score in patients with biopsy Gleason score ≤7].

Objective: To investigate the prognostic factors for clinically significant increase in post-prostatectomy Gleason score (pGS) in patients with biopsy Gleason score (bGS) ≤7.

Methods: This retrospective study included 170 cases of prostate cancer treated by radical prostatectomy in our hospital from January 2010 to December 2017. We analyzed the clinical and pathological data on the patients, including the age, preoperative serum tPSA, fPSA, fPSA / tPSA, prostate volume, PSA density (PSAD), and positive puncture rate of the patients with clinically significant elevation of pGS, as well as the possible factors for clinically significant pGS increase in patients with bGS = 7 and those with bGS ≤ 6.

Breviscapine (BVP) inhibits prostate cancer progression through damaging DNA by minichromosome maintenance protein-7 (MCM-7) modulation.

Naturally occurring compounds are reported as effective candidates for prevention and treatment of various cancers. Breviscapine (BVP) is a mixture of flavonoid glycosides, derived from the Chinese herbs. Previous researches have indicated that BVP has comprehensive pharmacological functions.

[Adenovirus-mediated combined gene therapy of interleukin-18 and interleukin-12 for prostate cancer: an experimental study].

Objective: To explore the therapeutic regimens of metastatic prostate cancer so as to provide the experimental rationales for its gene therapy.

Methods: The adenoviral vectors expressing cytokines interleukin-18 (IL-18) and interleukin-12 (IL-12) were used to induce tumor regression in a C57BL/6 murine model of prostate cancer (n = 110).

Results: Adenoviral vectors could express IL-18 and IL-12 effectively.